Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.97 is 52% above its 3-year average of -6.16, near the high end of its 3-year range (-17.83–-1.00).
68.45% above its 12-month average of -9.41.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.71.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 2 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.97
EARNINGS PER SHARE (EPS) AVG TTM
-9.41
EARNINGS PER SHARE (EPS) AVG 3Y
-6.16
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.45%
CURRENT VS 3Y AVG
+51.81%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$988.25M
Earnings Per Share (EPS)
-2.97
TTM Avg
-9.41
3Y Avg
-6.16
5Y Avg
N/A
Market Cap
$989.80M
Earnings Per Share (EPS)
-1.94
TTM Avg
-1.73
3Y Avg
-1.92
5Y Avg
-1.76
Market Cap
$991.73M
Earnings Per Share (EPS)
0.71
TTM Avg
-1.77
3Y Avg
-1.98
5Y Avg
-1.86
Market Cap
$981.28M
Earnings Per Share (EPS)
0.35
TTM Avg
-0.99
3Y Avg
-0.18
5Y Avg
0.61
Market Cap
$996.14M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$996.75M
Earnings Per Share (EPS)
N/A
TTM Avg
-52.25
3Y Avg
-46.52
5Y Avg
-41.75
Market Cap
$1.01B
Earnings Per Share (EPS)
-3.37
TTM Avg
-3.42
3Y Avg
-2.02
5Y Avg
-1.79
Market Cap
$965.56M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.23
3Y Avg
-0.94
5Y Avg
-0.94
Market Cap
$1.02B
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.08
3Y Avg
-1.22
5Y Avg
-1.11
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $988.25M | -2.97 | -9.41 | -6.16 | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $989.80M | -1.94 | -1.73 | -1.92 | -1.76 |
| MeiraGTx Holdings plc (MGTX)vs › | $991.73M | 0.71 | -1.77 | -1.98 | -1.86 |
| Pacira BioSciences, Inc. (PCRX)vs › | $981.28M | 0.35 | -0.99 | -0.18 | 0.61 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.14M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $996.75M | N/A | -52.25 | -46.52 | -41.75 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -3.37 | -3.42 | -2.02 | -1.79 |
| Aktis Oncology, Inc. (AKTS)vs › | $965.56M | -1.05 | -1.23 | -0.94 | -0.94 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -0.66 | -0.08 | -1.22 | -1.11 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -0.38 | -0.83 | -0.98 | -0.98 |
Trailing EPS (TTM)
$-2.97
Forward EPS (Est.)
$-5.63
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.00 |
| 2024-12-31 | -17.83 |
| 2023-12-31 | -1.77 |
| 2022-12-31 | -4.05 |
